Lioton (Heparin Sodium)

Heparin sodium binds to antithrombin III, dramatically increasing the inhibitor’s ability to inactivate thrombin and factor Xa. This blocks the final steps of the coagulation cascade, limiting fibrin generation and thereby preventing clot formation at the site where the product is applied.

The specific dose and frequency of Lioton are determined by the prescribing clinician based on the patient’s condition, the procedure involved, and individual risk factors. Healthcare professionals tailor the amount applied to achieve the desired anticoagulant effect while minimizing bleeding risk.

Safety data for topical heparin sodium during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with an obstetrician or qualified healthcare provider.

To order Lioton, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lioton provides a topical route, delivering heparin directly to the skin, which can limit systemic exposure compared with intravenous or oral anticoagulants. While it offers localized clot‑prevention, it does not replace systemic agents when broader anticoagulation is required, and its efficacy is best suited for surface‑related procedures.

Lioton should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the container tightly closed when not in use and avoid exposure to extreme temperatures, which could affect product stability and potency.

Lioton is applied cutaneously to the intended area using a sterile technique. The prescriber determines the amount and frequency, typically spreading a thin layer over the skin surface of the surgical site, dialysis circuit, or catheter insertion point, ensuring even coverage without excessive buildup.

The most serious risks include severe bleeding, heparin‑induced thrombocytopenia (HIT), and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of excessive bleeding, sudden drops in platelet count, or any systemic hypersensitivity symptoms while using the product.

Lioton should be avoided in patients with known hypersensitivity to heparin or any excipients, active uncontrolled bleeding, severe thrombocytopenia, or a history of heparin‑induced thrombocytopenia. It is also contraindicated in individuals with recent major surgery where systemic anticoagulation is not indicated.